Combining Desidustat with Erythropoietin: Not Recommended

Mechanistic Rationale Against Combination

Combining two erythropoietic agents, such as desidustat and erythropoietin (EPO), would create additive stimulation of red blood cell production, substantially increasing the risk of exceeding safe hemoglobin targets in patients with chronic kidney disease (CKD) 1, 2

Target hemoglobin levels must remain between 10-12 g/dL for all anemia treatments in CKD, as multiple large trials demonstrate increased cardiovascular events, stroke, and mortality when hemoglobin exceeds 12 g/dL, according to the American College of Cardiology 1, 2, 3
ESAs (including EPO) are associated with increased risk for thromboembolic events, short-term mortality, and decreased overall survival across different patient groups, making combination therapy with another erythropoietic agent particularly hazardous, as stated by the American Society of Clinical Oncology 4

EPO injections should be initiated only after iron stores have been corrected (TSAT ≤30%, ferritin ≤500 ng/mL addressed), other reversible causes treated, and hemoglobin remains below 10 g/dL, as recommended by the National Kidney Foundation 2, 3

The only clinical context where combining an erythropoietic agent with another medication is conditionally recommended involves hydroxyurea (not desidustat) with EPO in sickle cell disease patients with CKD, and this is based on very low certainty evidence with specific hemoglobin thresholds not exceeding 10 g/dL, according to the American Society of Hematology 5, 6, 7

Regular monitoring of hemoglobin levels is necessary to maintain target range of 10-12 g/dL, as recommended by the European Renal Association 1
Iron status (TSAT and ferritin) should be monitored at least every 3 months during treatment, according to the Kidney Disease: Improving Global Outcomes (KDIGO) guideline 2